A PHASE Ib, MULTICENTER, OPEN-LABELSTUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABL
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
July 24, 2019
End Date
December 8, 2023
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
July 24, 2019
End Date
December 8, 2023